Stockscreener 앱 받기
13.18
0.73%
0.095
시간 외 거래:
13.25
0.07
+0.53%
전일 마감가:
$13.09
열려 있는:
$13.1
하루 거래량:
150.35K
Relative Volume:
0.24
시가총액:
$731.86M
수익:
-
순이익/손실:
$-117.99M
주가수익비율:
-6.1597
EPS:
-2.1397
순현금흐름:
$-79.92M
1주 성능:
+0.30%
1개월 성능:
+18.42%
6개월 성능:
-55.52%
1년 성능:
-26.16%
1일 변동 폭
$12.87
$13.25
1주일 범위
$12.87
$13.70
52주 변동 폭
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
13.18 | 729.64M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat
Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci
Oculis Holding AG (OCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights - Stock Titan
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - The Manila Times
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ... - pmg-ky3.com
Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares - Bitget
Oculis acquires full rights to Privosegtor, boo... - Pluang
Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase - Quiver Quantitative
Oculis Signs Asset Purchase Agreement with Accure - GlobeNewswire
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results - MarketBeat
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Oculis Holding earnings beat by CHF0.23, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell - MarketBeat
Oculis Holding AG (OCS) Stock News Today - TradingKey
Oculis Holding AG (OCS) Stock Analysis: Navigating a 190.92% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oculis Holding AG Stock 12‑Month Price Target Cut to $36.26, Implies 193% Upside - TradingView
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Oculis Holding AG reports results for the quarter ended June 30Earnings Summary - TradingView
Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs - TradingKey
OCS: Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth - TradingView
Oculis (NASDAQ: OCS) pivots to neuro-ophthalmology as H1 loss falls - stocktitan.net
Oculis Reports Q2 2026 Financial Results and Provides Company Update - The Manila Times
Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result - Yahoo Finance
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses - Quiver Quantitative
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - Yahoo Finance Singapore
FDA Says Oculis Can Cross-Reference Data for Planned MS Relapse Trial - Stock Titan
Oculis Holding (OCS) Holds Near $11.31 as Buyers Defend Key Support ZoneStock Picks - vinanet.vn
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Oculis Holding AG Revenue Breakdown – NASDAQ:OCSAW - TradingView
Insiders At Oculis Holding Sold CHF1.0m In Stock, Alluding To Potential Weakness - simplywall.st
OCS|Oculis Holding AG|Price:10.952|Chg%:-0.068 - TradingKey
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OCS|Oculis Holding AG|Price:11.010|Chg%:-0.120 - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):